Takeda Discontinues Ramelteon Development In Europe
This article was originally published in PharmAsia News
Takeda Pharmaceutical had decided to halt development of Rozerem (ramelteon) in Europe for patients with insomnia
You may also be interested in...
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.
As well as highlighting Novartis's burgeoning pipeline, the Swiss major's CEO is confident that its biggest earners will continue to growth for the next five years at least.